ICCM Icecure Medical
- 1.190
- +0.010+0.85%
- 1.200
- +0.010+0.84%
Icecure Medical News
As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response
USA News Group – An alarming rise in early-onset cancers has medical experts very concerned, as cancer cases in younger people are rising sharply. In ...
Analysts Offer Insights on Healthcare Companies: Icecure Medical (ICCM), Viracta Therapeutics (VIRX) and Bioxcel Therapeutics (BTAI)
IceCure Medical Announces Upcoming Shareholders Meeting
IceCure Medical Eyes FDA Approval With Promising Trial Results
IceCure Medical Seeks FDA Nod For ProSense to Treat Early-Stage Breast Cancer
IceCure Medical (ICCM) said it has submitted final data to the US Food and Drug Administration seeking marketing authorization for ProSense to treat early-stage T1 invasive breast cancer patients with
Express News | Icecure Medical Reports Final Ice3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer
IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer
Data presentation at highly influential American Society of Breast Surgeons ("ASBrS") Annual Meeting by Dr. Richard Fine wins Scientific Impact Award as voted by breast surgeons.
Icecure Medical: Strong Buy on Impressive Q4 Revenue and Promising Regulatory Milestones
Analysts Offer Insights on Healthcare Companies: Cocrystal Pharma (COCP) and Icecure Medical (ICCM)
Icecure Medical in Jeopardy: Navigating Nasdaq Delisting Risks and Future Uncertainties
Express News | Icecure Medical Q4 EPS $(0.07), Inline, Sales $1.25M Beat $1.17M Estimate
Earnings Call Summary | Icecure Medical(ICCM.US) Q4 2023 Earnings Conference
The following is a summary of the IceCure Medical Ltd. (ICCM) Q4 2023 Earnings Call Transcript:Financial Performance:IceCure's revenues saw a year-on-year increase of 26% to $3 million from sales of P
IceCure Medical Reports FY Results
IceCure Medical's Sales Surge as FDA Review Looms
Express News | As Of March 31, 2024, IceCure Medical Had Cash And Cash Equivalents Of Approximately $11M, IceCure Has Implemented An Expense Reduction Plan Lowering The Monthly Cash Utilization And Ensuring It Can Meet Its Primary Goals In 2024
Icecure Medical FY EPS $(0.32), Inline, Sales $3.23M Beat $3.14M Estimate
Icecure Medical (NASDAQ:ICCM) reported quarterly losses of $(0.32) per share which met the analyst consensus estimate. This is a 30.43 percent increase over losses of $(0.46) per share from the same p
Earnings Scheduled For April 3, 2024
Companies Reporting Before The Bell • Acuity Brands (NYSE:AYI) is projected to report quarterly earnings at $3.25 per share on revenue of $907.75 million. • Icecure Medical (NASDAQ:ICCM) is estimated
IceCure Medical Seeks FDA Clearance for Cryoablation Technology
IceCure Medical (ICCM) said Tuesday it filed an application with the US Food and Drug Administration for clearance of XSense, a single probe cryoablation technology. The 501(k) submission for XSense c
Express News | IceCure Submits 510(k) With FDA For Clearance Of XSense Cryoablation System With Cryoprobes
IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024
Eyal Shamir, Chief Executive Officer, and Ronen Tsimerman, Chief Financial Officer, will discuss the operating and financial results, and other corporate developments on a conference call at 10:00 a.m. EDT on the same day.
Analysis
Price Target
No Data
